Osmotica Pharmaceuticals plc
Company Name | Osmotica Pharmaceuticals plc |
Stock Symbol | OSMT |
Class Period | October 14, 2018 to April 26, 2019 |
Lead Plaintiff Motion Deadline | April 26, 2019 |
On March 27, 2019, after the markets closed, Osmotica announced preliminary results for a second Phase 3 clinical trial of arbaclofen extended-release tablets that failed to beat placebo as measured by the Clinical Global Impression of Change. On this news, shares of Osmotica fell $2.74, or nearly 41%, to close at $4.00 on March 28, 2019, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Osmotica Pharmaceuticals plc investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.